EARKART.BO · BSE
EARKART LIMITED
₹151.95
+15.73% (+₹20.65)
Prev. close
₹131.3
Volume
1,000
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About EARKART LIMITED
Earkart Limited manufactures and distributes modern hearing aids and related accessories in India and internationally. The company offers adjustable foldable walkers; Multi Sensory Inclusive Educational (MSIED) Kit designed for educational purpose for mentally retarded children; Teaching Learning Material (TLM) kits to support mobility and daily needs of physically challenged; and other rehabilitation products, including their components, accessories, and parts. It also provides hearing aid test systems; BTE kit component; and zinc air battery. Additionally, the company offers after-sales services; user training; and research and development of hearing aids. Earkart Limited was incorporated in 2021 and is based in Noida, India.
Details
Sector
Healthcare
Industry
Medical Devices
CEO
Mr. Rohit Misra
Headquarters
Noida
Employees
58
Website
earkart.inExchange
View on BSE ↗Key stats
Market cap
₹208.99 Cr
P/E ratio (TTM)
38.0
EPS (TTM)
₹4.00
Beta (1Y · daily vs NIFTY 50)
0.12
Shares float
46.70 L
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹28.92 Cr | ₹31.75 Cr | ₹43.11 Cr | ₹54.04 Cr | |
| EBITDA | ₹1.62 Cr | ₹3.61 Cr | ₹9.86 Cr | ₹8.46 Cr |
| ₹1.31 Cr | ₹3.06 Cr | ₹6.88 Cr | ₹4.94 Cr | |
| Diluted EPS | ₹0.95 | ₹2.22 | ₹5 | ₹3.99 |
Total expenses (as filed), Employee benefit expense, Other expenses have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹14.73 Cr | ₹19.25 Cr | ₹30.29 Cr | ₹69.49 Cr | |
| ₹1.21 Cr | ₹4.00 Cr | ₹4.96 Cr | ₹24,110 | |
| Stockholders' equity | ₹6.56 Cr | ₹13.03 Cr | ₹19.92 Cr | ₹64.35 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹-29.64 L | ₹-99.73 L | ₹71.13 L | ₹-12.56 Cr | |
| Investing cash flow | ₹39.88 L | ₹-1.29 Cr | ₹-1.31 Cr | ₹-5.18 Cr |
| Financing cash flow | ₹40.70 L | ₹3.08 Cr | ₹-40.86 L | ₹39.06 Cr |
| Capital expenditure | ₹-18.24 L | ₹-99.11 L | ₹-53.45 L | ₹-5.37 Cr |
| End cash position | ₹58.20 L | ₹1.38 Cr | ₹36.64 L | ₹21.69 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| EARKART LIMITED | ₹180.59 Cr | ₹131.3 | 32.9 | 2.81 | 7.7% | 0.00 | +25.4% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
1 index
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.